EPO Patents = 1

Forward Citations = 2

Loading Chart...

8 inventors (with patents filed for the assignee):

Xiangyang Chen (6 out of 19 patents)

Yingxiang Gao (4 out of 10 patents)

Haihong Ni (4 out of 7 patents)

4. Chong Liu (4 out of 25 patents)

5. Mark Mulvihill (2 out of 2 patents)

6. Yucheng Pang (1 out of 5 patents)

7. Norman Xianglong Kong (1 out of 6 patents)

8. Chao Zhou (1 out of 6 patents)

6 patents: Sort by Forward Citations

1. 12448382 - Heterocyclic compounds for mediating tyrosine kinase 2 activity (2025-10-21),

2. 12162873 - Substituted nicotinimide inhibitors of BTK for treating cancer (2024-12-10),

3. 11840513 - Substituted nicotinimide inhibitors of BTK for treating cancer (2023-12-12),

4. 11345695 - Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease (2022-05-31),

5. 10752631 - Heterocyclic compounds as FGFR inhibitors (2020-08-25),

6. 10301297 - Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease (2019-05-28),

Guangzhou Innocare Pharma Tech Co., Ltd. is a leading pharmaceutical company specializing in research, development, and production of high-quality pharmaceutical products. With a focus on innovation and customer satisfaction, we strive to provide effective and safe healthcare solutions to improve the quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

6 Patents

#85 in Guangzhou

#3,913 in China

Guangzhou, China

Guangzhou Innocare Pharma Tech Co., Ltd.